Introduction
Salivary gland tumors (SGTs) are among the relatively rare group of neoplasms characterized by the wide range of biological behaviors and a variety of benign and malignant types. The annual incidence of SGTs is approximately 0.4 to 13.5 cases per 100,000 individuals, about 3-6% of all head and neck cancers [1] [2] [3] [4] . SGTs are considered to have multifactorial etiology, and histopathologic characteristic complicates their diagnosis and management. The management requires distinctive surgical and adjuvant therapy, but the early detection plays an important role in successful therapy and reduces the severity of its impact on the patient's life [3] [4] . Despite a low prevalence, a number of factors such as the complex histopathological diagnosis, grade of malignancies, varied clinical behaviors and risk of recurrence pose the major challenges for the pathologists and clinicians to achieve the effective treatment [3] [4] [5] .
Paxillin is a 68-kDa focal adhesion-associated adaptor protein, which is originally identified as a tyrosine phosphorylated protein in chick embryo fibroblasts.
Paxillin is localized at the intracellular surfaces where the cells adhere to the extracellular matrix. The function has not been well characterized, but it has been proposed that paxillin acts as an oncogene in many malignancies and involved in key signal transduction, cell motility, migration, proliferation, survival, angiogenesis, and apoptosis [6] [7] [8] [9] [10] . A number of studies have been evaluated the expression of paxillin and shows the deregulation and its role in the development of various human carcinomas such as the squamous cell carcinoma [11] , esophageal squamous cell carcinoma [12] , lung [13] [14] , breast [15] , cervical [16] , colorectal [9] , and prostate cancers [17] [18] . Furthermore, it was shown that paxillin level significantly associated with the progression and metastasis of malignancies. Patients with high paxillin expression had poorer prognosis and survival rate compared to those with low paxillin expression.
However, the underlying mechanisms of paxillin overexpression remain unresolved. Therefore, paxillin might be a potential therapeutic target to suppress tumor progression [6, 9, [19] [20] [21] . To the best of our knowledge and among the different type of SGTs, only one study has evaluated the expression of paxillin in patients with salivary adenoid cystic carcinoma (ACC) [22] . However, the role and its expression in the other types of SGTs still need to be clearly elucidated. Therefore, the current study aimed to determine the expression levels of paxillin and its prognostic and clinicopathological significance in Iranian patients with benign and malignant SGTs.
Materials and Method

Study Population
A total of 50 paraffin-embedded SGTs tissues from patients who underwent surgery in the ENT department more than 4 was rated as "high" paxillin expression whereas a score less than 4 was rated as "low" paxillin expression [8] .
Statistical analysis
The statistical analysis was performed using the SPSS software package (version 21, SPSS Inc, Chicago, USA). The comparison of paxillin expression and association between clinicopathological characteristics and paxillin expression was analyzed by the chi-square and ANOVA test. A p value of less than 0.05 was considered statistically significant.
Results
Paxillin was mainly localized in the cytoplasm of tumor cells and all samples (100%) included in this study was expressed paxillin (Table 1) .
Paxillin expression was mainly seen in ductal cells of NSG. In PA and ACC both ductal and myoepithelial cells showed paxillin positivity (Figures 1 to 4 ). Paxillin was highly expressed in 66% of our patients, which is similar to the results of patients with hepatocellular carcinoma [26] , but differs from urothelial bladder tumor [30] . On the other hand, all the patients with NSG rated as low paxillin expression. In accordance to our results, almost all previous studies such as those conducted on patients with laryngeal squamous cell carcinoma [20] , esophageal squamous cell carcinoma [12] , colorectal cancer [8] , lung cancer [13] , gastric cancer [6] , and colorectal cancer [9] show the higher expression of paxillin in cancerous tissues compared with that of observed in their controls. Furthermore, paxillin could not differentiate between benign and malignant cases. Our results revealed that paxillin expression was not correlated with clinicopathological parameters of patients with SGTs. It is in contrast with the results of Shi et al. [22] in which paxillin expression was associated with clinical stage and distant metastasis, but not with histologic type. Similar results were obtained in patients with colorectal cancer [19, 31] , and hepatocellular carcinoma [26] .
High expression of paxillin was significantly correlated with the advanced TNM stage in gastric cancer [6] , prostate cancer [32] , colorectal cancer [19] , laryngeal squamous cell carcinoma [20] , and salivary ACC [22] . However, the relationship between paxillin expression and advanced clinical stages was not reached in this study, because of small sample size of malignant tumors. So due to the relatively small number of samples, further investigation of its potential is highly warranted, especially when early detection of patients could improve the prognosis and survival rate.
In summary, the present study showed that paxillin expression of SGTs was significantly higher than NSG, which highlight the important role of paxillin expression in the development of tumors. However, it is not correlated with clinicopathologic factors of patients. Our study had some limitations. First, this is a retrospective study and not well controlled. In addition, this study concerned the small number of patients and relatively few clinical events, limiting our ability for precise conclusions. Further studies with larger sample size will be required to assess the potential roles of paxillin for the early detection of SGTs.
Conclusion
High expression of paxillin was observed in tumoral tissues compared with the controls that establish an important role of paxillin in SGTs but its prognostic role was unclear and need further evaluation.
